Opinion|Videos|January 3, 2025
EGFR mNSCLC: Challenges with Treatments in this Space
A panelist discusses how managing resistance mechanisms and toxicity profiles and identifying optimal sequencing strategies remain key challenges in treating EGFR-mutated metastatic non–small cell lung cancer despite advances in targeted therapies.
Advertisement
Episodes in this series
Advertisement
Related to this article
Experts in multiple myeloma discussed long-term MAIA and CEPHEUS trial data and their implications for daratumumab-based regimens in newly diagnosed disease.
Advertisement
Advertisement
Trending on CancerNetwork
1
FDA Approves Atezolizumab/Chemo for Stage III dMMR Colon Cancer
2
Building out a Radiopharmaceuticals Program in Oncology Care
3
Iberdomide Combination Doubles PFS vs SOC Therapy in R/R Multiple Myeloma
4
How Would a TALAPRO-3 Approval Affect HRR-Altered Metastatic HSPC Care?
5